Novartis (NVS) stock dropped 3% after pelacarsen failed its cardiovascular outcomes trial, raising concerns about Lp(a)-targeting therapies. The post Novartis (NVS) Stock Drops 3% as Pelacarsen Heart Drug Disappoints in Key Trial appeared first on Blockonomi.